Literature DB >> 11739706

Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.

Gabriel M Ortiz1, Jennifer Hu, Joshua A Goldwitz, Rohit Chandwani, Marie Larsson, Nina Bhardwaj, Sebastian Bonhoeffer, Bharat Ramratnam, Linqi Zhang, Martin M Markowitz, Douglas F Nixon.   

Abstract

Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have preserved HIV-1-specific CD4+ T-cell function. We studied the effect of highly active antiretroviral therapy (HAART) on the frequency of HIV-1-specific CD8+ T cells in patients treated during early (n = 31) or chronic (n = 23) infection. The degree of viral suppression and time of initiation of treatment influenced the magnitude of the CD8+ T-cell response. HIV-1-specific CD8+ T cells can increase in number after HAART in subjects treated early after infection who have episodes of transient viremia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11739706      PMCID: PMC135693          DOI: 10.1128/jvi.76.1.411-415.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia.

Authors:  J Wilkinson; J J Zaunders; A Carr; D A Cooper
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

2.  Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.

Authors:  O Pontesilli; S Kerkhof-Garde; D W Notermans; N A Foudraine; M T Roos; M R Klein; S A Danner; J M Lange; F Miedema
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

3.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

4.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.

Authors:  M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

5.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

6.  Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

Authors:  H F Günthard; S D Frost; A J Leigh-Brown; C C Ignacio; K Kee; A S Perelson; C A Spina; D V Havlir; M Hezareh; D J Looney; D D Richman; J K Wong
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

7.  Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).

Authors:  C M Gray; J Lawrence; J M Schapiro; J D Altman; M A Winters; M Crompton; M Loi; S K Kundu; M M Davis; T C Merigan
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

Review 8.  The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.

Authors:  S A Kalams; B D Walker
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

9.  Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.

Authors:  R D Hockett; J M Kilby; C A Derdeyn; M S Saag; M Sillers; K Squires; S Chiz; M A Nowak; G M Shaw; R P Bucy
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

10.  Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P Moss; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; A Hurley; M Markowitz; D D Ho; A J McMichael; D F Nixon
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  9 in total

1.  Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model.

Authors:  Hongying Shu; Lin Wang; James Watmough
Journal:  J Math Biol       Date:  2013-01-11       Impact factor: 2.259

2.  Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.

Authors:  Nonhlanhla N Mkhize; Pamela P Gumbi; Lenine J Liebenberg; Yuan Ren; Peter Smith; Lynette Denny; Jo-Ann S Passmore
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.

Authors:  Edith Jasny; Suzanne Geer; Ines Frank; Panagiotis Vagenas; Meropi Aravantinou; Andres M Salazar; Jeffrey D Lifson; Michael Piatak; Agegnehu Gettie; James L Blanchard; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

4.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.

Authors:  Christie Joya; Seung Hyun Won; Christina Schofield; Tahaniyat Lalani; Ryan C Maves; Karl Kronmann; Robert Deiss; Jason Okulicz; Brian K Agan; Anuradha Ganesan
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

6.  Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success.

Authors:  Natalia L Komarova; Eleanor Barnes; Paul Klenerman; Dominik Wodarz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

7.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.

Authors:  Pedro Castro; Montserrat Plana; Raquel González; Anna López; Anna Vilella; Jose M Nicolas; Teresa Gallart; Tomàs Pumarola; José M Bayas; José M Gatell; Felipe García
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-16       Impact factor: 2.205

9.  Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.

Authors:  Michele Di Mascio; Martin Markowitz; Michael Louie; Arlene Hurley; Christine Hogan; Viviana Simon; Dean Follmann; David D Ho; Alan S Perelson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.